Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule

Clinical Pharmacokinetics(2023)10.1007/s40262-023-01267-xSource: DataRank Database

Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule is a research paper published in Clinical Pharmacokinetics (2023). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.37)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Jennifer E. Golden ORCID,Colleen B. Jonsson ORCID,Bernd Meibohm ORCID,Zaid H. Temrikar

Live enrichment

PubMed:37326917 PMC:PMC10471120 OpenAlex:https://openalex.org/W4380872732

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: U19AI142762

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: U19AI171292

National Institutes of Health

Grant: 1U19AI171292-01

RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER (READDI-AC)

National Institutes of Health

Grant: 5U19AI142762-04

Center of Excellence for Encephalitic Alphavirus Therapeutics

FWCI

0.37

Citation Percentile

0.5%

Citation Trend

2023

2024

2025

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10471120/pdf/nihms-1924085.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40262-023-01267-x.pdf

publisherhttps://link.springer.com/article/10.1007/s40262-023-01267-x/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10471120

Fields of Study

Bacillus and Francisella bacterial researchAnimal testing and alternativesBiosimilars and Bioanalytical Methods0403 veterinary science04 agricultural and veterinary sciencesAnimalsUnited StatesHumansDrug ApprovalUnited States Food and Drug AdministrationPharmaceutical PreparationsAnti-Infective AgentsBiological Factors

MeSH Terms

AnimalsAnti-Infective AgentsBiological FactorsPharmaceutical PreparationsHumansUnited StatesUnited States Food and Drug AdministrationDrug Approval

Keywords

MedicineClinical trialContext (archaeology)PharmacologyDrugFood and drug administrationHuman useDosingClinical pharmacologyDrug approvalAnimal testingSafety pharmacologyHuman studiesIntensive care medicineBiotechnologyBiologyPathologyInternal medicineBiological FactorsPharmaceutical PreparationsAnti-Infective AgentsUnited States Food and Drug AdministrationAnimalsHumansUnited States

Sustainable Development Goals

SDG 0: Good health and well-being

Clinical and Translational Pharmacology Considerations for Anti-infectives Approved Under the FDA Animal Rule

FAIR Checklist

Authors (4)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)